ALKBH5 and neoplasm: Growing evidence has demonstrated that m6A modification is closely associated with tumorigenesis, tumor differentiation, tumor proliferation, tumor invasion and worse survival in BC patients, including METTL3, METTL14, WTAP, ALKBH5, IGF2BP2, IGF2BP3, and FTO [3–14].